Social media

PubsHub Journals & Congresses are indexed by Clarivate Analytics, with updated impact factors and Journal Citation Reports (JRC) categories annually. Use the information to pick the resource that best matches your goals....

PubsHub Journals & Congresses are indexed by Clarivate Analytics, with updated impact factors and Journal Citation Reports (JRC) categories annually. Use the information to pick the resource that best matches your goals....

ICON will be at #EBF, 18–20 November. Visit booth B-15 to meet our bioanalytical experts and learn how we support drug development with regulatory-compliant solutions. https://ow.ly/L0x150XiU3t

ICON will be at #EBF, 18–20 November. Visit booth B-15 to meet our bioanalytical experts and learn how we support drug development with regulatory-compliant solutions. https://ow.ly/1ECG50XiU3s

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Implementing digital health technologies in clinical trials is promising, but doing it well means more than just selecting the right tools. From training and compliance monitoring to real-time data readiness, success de...

Clinical development is under pressure: rising costs, long timelines, complex designs. The solution? A digitally enabled, patient-centered approach. In this whitepaper, we explore how Digital Health Technologies are tra...

Pregnant women remain significantly underrepresented in clinical trials, leading to critical data gaps in drug safety and efficacy. ICON’s Liz O’Brien underscores the importance of building trust, fostering transparency,...

The specific needs of oncology clinical trials, alongside the distinct clinical pathway for biosimilars, mean that developing these treatments must be approached very differently from novel biologic development. To under...

Oncology biosimilars present unique potential and distinct challenges to sponsors. The specific needs of oncology clinical trials, alongside the distinct clinical pathway for biosimilars, mean that developing these tre...

Metabolic dysfunction-associated steatohepatitis (MASH) is rapidly becoming one of the leading causes of liver-related morbidity and mortality — yet it remains underdiagnosed and under-recognised. In our latest blog, fr...